- SEK1.36bn
- SEK1.05bn
Brief: Flerie Portfolio Co Reports Positive Data From Clinical Proof-Of-Mechanism Study
Brief: Flerie Writes Down Value Of Holding In Empros Pharma
Brief: Nasdaq Approves Biosergen's Delisting Application
Brief: Flerie Approves Merger Plan For Flerie And Biosergen
Brief: Flerie Q2 NAV Per Share Down 2.9%
Brief: Flerie's Bonsai Biotherapeutics Gets Clinical Trial Application Approval
Brief: Flerie Portfolio Firm Reports Positive Bladder Cancer Data
Brief: Flerie Completes Bonus Issue
Brief: Flerie Majority Owner Waives Share Allocation
Brief: Flerie To Redeem All Outstanding Series C Shares
Brief: Flerie Q1 Net Result At SEK -61 Million
Brief: Flerie, Lipum Merger Plan Approved
Brief: Flerie's Lipum Selected For EUR 8 Million Horizon Europe Grant
Brief: Flerie Decides On SEK 76 Mln Directed Share Issue
Brief: Microbiotica Reports Positive Phase 1B Data For MB310
Brief: Flerie's Portfolio Company Nanologica Acquires Syntagon
Brief: Flerie Proposes No Dividend Be Paid For 2025
Brief: Flerie’s Portfolio Company Chromafora Buys Montrose Environmental Group Denmark
Brief: Kahr Bio Secures $22 Mln In Equity Funding